Drug combination for rare kidney conditions from abnormal proteins
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests a combination of two drugs (daratumumab and bortezomib, plus a steroid called dexamethasone) for people with rare kidney conditions caused by abnormal proteins. The treatment targets the abnormal plasma cells to help protect your kidneys and improve your health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a rare kidney condition linked to abnormal proteins (called MGRS).
- A bone marrow test has found abnormal plasma cells (a type of immune cell).
- You are generally able to do daily activities (score of 0, 1, or 2 on a standard scale).
- Your blood counts are within safe levels (hemoglobin at least 70, platelets at least 50).
- Your liver function is not severely impaired (bilirubin and liver enzymes within 3 times the upper limit).
- You have not had prior treatment for this kidney condition, aside from a brief course of steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a new combination of drugs (daratumumab, bortezomib, and dexamethasone) against the usual combination (cyclophosphamide, bortezomib, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney failure. The goal is to see if the new combination works better and helps protect kidney function.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Hear when a new Monoclonal Gammopathy of Renal Significance (MGRS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.